Anderson T M, Ray C W, Nwogu C E, Bottiggi A J, Lenox J M, Driscoll D L, Urschel J D
Department of Thoracic Surgical Oncology,State University of New York & Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
J Cardiovasc Surg (Torino). 2001 Jun;42(3):415-9.
Approximately 21% of patients with advanced malignancies have cardiac or pericardial involvement with tumor. Controversy exists regarding the optimal approach to the pericardial space when hemodynamic compromise due to effusions occurs.
A six-year retrospective review of 59 cancer patients with pericardial effusions.
Thirty-six patients had subxiphoid pericardial window (SXPW) alone (Group A), 5 had pericardial catheter drainage (PCD) followed by a SXPW (Group B), 10 had PCD with sclerosis (Group C), 5 had PCD alone (Group D), 2 had PCD with pericardial-pleural window (Group E), and one had pericardial-peritoneal window (Group F). The method of procedure, complications, number of hospital and ICU days, cytological or pathologic evidence of malignancy, solid versus hematological tumors, and survival were analyzed. The median survival for those patients in group C was one month compared to 4 months for Group A and 6 months for Group B. Essentially, results were similar regardless of method performed with the exception that professional and hospital charges averaged $4830 for SXPW compared to $1625 for PCD.
Pericardial catheter drainage and sclerosis provides a viable option for the treatment of pericardial effusions in selected cancer patients at markedly reduced cost and patient discomfort.
约21%的晚期恶性肿瘤患者存在心脏或心包的肿瘤累及。当因积液导致血流动力学受损时,关于心包腔的最佳处理方法存在争议。
对59例心包积液癌症患者进行为期六年的回顾性研究。
36例患者仅接受剑突下心包开窗术(A组),5例先接受心包置管引流(PCD),随后接受剑突下心包开窗术(B组),10例接受PCD并硬化治疗(C组),5例仅接受PCD(D组),2例接受PCD并心包胸膜开窗术(E组),1例接受心包腹膜开窗术(F组)。分析了手术方法、并发症、住院天数和重症监护病房天数、恶性肿瘤的细胞学或病理学证据、实体瘤与血液系统肿瘤以及生存率。C组患者的中位生存期为1个月,而A组为4个月,B组为6个月。基本上,无论采用何种方法,结果相似,唯一的例外是剑突下心包开窗术的专业和医院收费平均为4830美元,而PCD为1625美元。
心包置管引流并硬化治疗为部分癌症患者心包积液的治疗提供了一种可行的选择,可显著降低成本并减轻患者不适。